BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kontos AP, Kerr HA, Fivenson DP, Remishofsky C, Jacobsen G. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol. 2006;45:1383-1385. [PMID: 17076739 DOI: 10.1111/j.1365-4632.2006.03133.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Prajapati V, Man J, Brassard A. Pyoderma gangrenosum: common pitfalls in management and a stepwise, evidence-based, therapeutic approach. J Cutan Med Surg 2009;13 Suppl 1:S2-11. [PMID: 19480746 DOI: 10.2310/7750.2009.00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
2 Sehgal VN, Srivastava G, Dogra S. Tacrolimus: Approved and Unapproved Dermatologic Indications/Uses—Physician's Sequential Literature Survey: Part II. SKINmed 2008;7:73-7. [DOI: 10.1111/j.1751-7125.2008.06514.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
3 Rallis E, Korfitis C, Gregoriou S, Rigopoulos D. Assigning new roles to topical tacrolimus. Expert Opin Investig Drugs 2007;16:1267-76. [PMID: 17685874 DOI: 10.1517/13543784.16.8.1267] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
4 Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges 2017;15:34-40. [PMID: 28140549 DOI: 10.1111/ddg.13173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
5 Weedon D. The vasculopathic reaction pattern. Weedon's Skin Pathology. Elsevier; 2010. pp. 195-244.e49. [DOI: 10.1016/b978-0-7020-3485-5.00009-7] [Cited by in Crossref: 11] [Article Influence: 1.0] [Reference Citation Analysis]
6 Abdul-fattah B, Al-muriesh M, Huang C. Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum. Dermatologic Therapy 2018;31:e12697. [DOI: 10.1111/dth.12697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Oranje AP, Verbeek R, Verzaal P, Haspels I, Prens E, Nagelkerken L. Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. Br J Dermatol 2009;160:54-61. [PMID: 18795918 DOI: 10.1111/j.1365-2133.2008.08834.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Marzano AV, Trevisan V, Lazzari R, Crosti C. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. Journal of Dermatological Treatment 2010;21:140-3. [DOI: 10.3109/09546630903268239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
9 Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther 2012;25:158-72. [PMID: 22741935 DOI: 10.1111/j.1529-8019.2012.01488.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
10 Cecchi R, Pavesi M, Bartoli L, Brunetti L. Successful Treatment of Localized Pyoderma Gangrenosum with Topical Pimecrolimus. J Cutan Med Surg 2012;16:295-7. [DOI: 10.1177/120347541201600503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
11 Lu J, Hobbs M, Huang W, Ortega‐loayza A, Alavi A. Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review*. Br J Dermatol 2020;183:821-8. [DOI: 10.1111/bjd.19027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Hobbs MM, Ortega-Loayza AG. Pyoderma gangrenosum: From historical perspectives to emerging investigations. Int Wound J 2020;17:1255-65. [PMID: 32378319 DOI: 10.1111/iwj.13389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Panuncialman J, Falanga V. Unusual causes of cutaneous ulceration. Surg Clin North Am 2010;90:1161-80. [PMID: 21074034 DOI: 10.1016/j.suc.2010.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]